Rice researchers develop realistic ‘mock’ samples to speed cervical cancer test development
A team of Rice bioengineers has developed a new way to create highly realistic “mock” patient samples that could help accelerate the development of faster, more accessible cervical cancer screening tests for low-resource settings.
First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer
Rice researchers and collaborators at MD Anderson report results from a first-in-human trial evaluating a novel cell-based therapeutic platform in patients with advanced ovarian cancer.
AI-powered handheld microscope aims to spot cancer earlier
Researchers at Rice and The University of Texas MD Anderson Cancer Center have developed a compact, artificial intelligence-powered imaging device that could transform how clinicians detect cancer.
Rice bioengineering outreach event brings Houston students into the lab
Nearly 70 high school students from across the Houston area spent a weekend morning moving through different research labs at Rice University in order to get a firsthand view of what pursuing a professional path in science and engineering could entail.
Brain-computer interface based on Rice research wins FDA approval for first clinical trial
Motif Neurotech, a company commercializing technology based on research at Rice, has received approval from the FDA to begin the first clinical trial of its therapeutic brain-computer interface for treatment of treatment-resistant depression.
The Rice Biotech Launch Pad will advance the development of a cell-based therapy for Type 1 diabetes supported by an award from Breakthrough T1D.
An internal seed funding initiative will support 12 projects exploring brain health research.
Rice highlights ‘transformative’ cancer innovation, venture pipeline during CPRIT visit
Rice foregrounded its cancer research portfolio during a visit from Cancer Prevention and Research Institute of Texas senior officials.
RBL LLC launches Duracyte, advancing living pharmacy platform in Houston’s growing biotech hub
RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies, today announced the launch of Duracyte, a biotechnology company commercializing a pioneering class of implantable “biohybrid pharmacy” devices designed to produce therapeutic proteins continuously inside the human body.
Rice bioengineer to lead national organization, advocate for research funding on Capitol Hill
The Rice bioengineering department helped host the annual meeting of the American Institute for Medical and Biological Engineering, where two Rice faculty were inducted as Fellows and Michael King stepped in as president.
AI spots hidden behavior patterns in self-organizing bacteria
A custom-built artificial intelligence system developed by Rice researchers helped uncover how bacterial communities self-organize.
The Center for Innovation and Translation of Point-of-Care Technologies for Expanded Cancer Care Access, a Rice-led collaboration of partners from three continents and based in the Texas Medical Center, has announced its second round of subawardees.
Scientists uncover new method to generate protein datasets for training AI
Rice researchers develop an method to quickly produce protein activity data needed to train predictive AI models for improved protein function.
Solving the oxygen problem in cell-based drug delivery
Rice researchers and collaborators have now successfully integrated solutions to several persistent challenges to implantable drug factories into a single device.
Scalable platform sheds light on how cancer spreads
A new platform makes it easier to study metastasis and sheds light on how cancer clusters survive in the bloodstream when spreading from a primary tumor to other parts of the body.
